TABLE 2.

Aggregate Lipid-Lowering Treatment Rates Before and 1 Year After 2013 Cholesterol Guideline

	ASCVD (n = 301,440)			DM (n = 309,095)
	Preguideline	Postguideline	Std. Diff. (%)a	Preguideline	Postguideline	Std. Diff. (%)a
Cholesterol-lowering agents
Any statin	144,754 (48.0)	142,517 (47.3)	1.4	155,338 (50.3)	159,195 (51.5)	2.4
Low intensity	29,489 (20.4)	27,392 (19.2)	-	34,112 (22.0)	32,687 (20.5)	-
Moderate intensity	93,022 (64.3)	89,808 (63.0)	-	102,047 (65.7)	102,576 (64.4)	-
High intensity	22,243 (15.4)	25,317 (17.8)	-	19,179 (12.3)	23,932 (15.0)	-
Bile acid binding resins	2,426 (0.8)	2,238 (0.7)	1.2	2,833 (0.9)	2,599 (0.8)	1.1
Ezetimibe	6,851 (2.3)	6,074 (2.0)	2.1	6,712 (2.2)	6,010 (1.9)	2.1
Fibrates	11,606 (3.9)	10,812 (3.6)	1.6	19,928 (6.4)	18,892 (6.1)	1.2
Niacin	3,082 (1.0)	1,887 (0.6)	4.5	3,127 (1.0)	2,062 (0.7)	3.3
No lipid treatment	149,086 (49.5)	152,010 (50.4)	1.8	142,251 (46.0)	139,730 (45.2)	1.6
Treatment regimens
Statin	128,561 (42.6)	128,379 (42.6)	0.1	134,561 (43.5)	139,791 (45.2)	3.4
Nonstatin	7,600 (2.5)	6,913 (2.3)	1.3	11,506 (3.7)	10,170 (3.3)	2.2
Statin and nonstatin	16,193 (5.4)	14,138 (4.7)	3.2	20,777 (6.7)	19,404 (6.3)	1.6
No lipid treatment	149,086 (49.5)	152,010 (50.4)	1.8	142,251 (46.0)	139,730 (45.2)	1.6

Note: Values are represented as number (%) unless noted otherwise.

^a A standardized difference of >10% was considered a significant imbalance between proportions.

ASCVD = atherosclerotic cardiovascular disease; DM = diabetes mellitus; Std. Diff. = standardized difference.